SCHEMBL9106215

SCHEMBL9106215

CCCSC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 20/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl(Trityl)Sulfane SCHEMBL4755270 0.86 KIF11 (0.56) KIF11
SCHEMBL13741458 0.86 KIF11 (0.74) KIF11
SCHEMBL18599373 0.85 KIF11 (0.57) KIF11
SCHEMBL4613838 0.84 KIF11 (0.72) KIF11
Ethyl(Trityl)Sulfane SCHEMBL2772809 0.84 KIF11 (0.54) KIF11
SCHEMBL6909006 0.84 KIF11 (0.55) KIF11
SCHEMBL26224 0.84 KIF11 (0.55) KIF11
Ethyl(Trityl)Sulfane SCHEMBL16908567 0.82 KIF11 (0.52) KIF11
SCHEMBL4616348 0.82 KIF11 (0.55) KIF11
SCHEMBL12086374 0.78 KIF11 (0.54) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3947347-A1 PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOF Comet Therapeutics, Inc. (US) 2022-02-09 EP disclosed
EP-3394185-B1 NOVEL COMPOSITIONS AND USE THEREOF FOR MODIFICATION OF SUBSTRATE SURFACES MERCK PATENT GMBH (DE) 2020-12-09 EP disclosed
WO-2020198573-A1 PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOF COMET THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed
US-9821072-B2 Activated neurotensin molecules and the uses thereof VECT-HORUS (FR) 2017-11-21 US disclosed
US-20170174931-A1 NOVEL COMPOSITIONS AND USE THEREOF FOR MODIFICATION OF SUBSTRATE SURFACES AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) 2017-06-22 US disclosed
WO-2017068596-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)- 7-ETHYLIDENE-4,21-BIS(1-METHYLETHYL)-2-OXA-12,13-DITHIA-5, 8, 20, 23- TETRAAZABICYCLO[8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE MSN LABORATORIES PRIVATE LIMITED (IN) 2017-04-27 WO disclosed
US-20160354480-A1 ACTIVATED NEUROTENSIN MOLECULES AND THE USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-12-08 US disclosed
US-20160354480-A1 ACTIVATED NEUROTENSIN MOLECULES AND THE USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-12-08 US disclosed
WO-2015120287-A2 COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS YALE UNIVERSITY (US) 2015-08-13 WO disclosed
US-8609857-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2013-12-17 US disclosed
US-20100160645-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2010-06-24 US disclosed
US-7560588-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2009-07-14 US disclosed
US-7560588-B2 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES, INC. (US) 2009-07-14 US disclosed
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES (US) 2008-08-28 US disclosed
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups INTEZYNE TECHNOLOGIES (US) 2008-08-28 US disclosed
WO-2007127473-A2 POLY (ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS INTEZYNE TECHNOLOGIES, INC. (US) 2007-11-08 WO disclosed
EP-0482185-A4 CELL INTERNALIZABLE CONJUGATES AND COMPLEXES INCLUDING INTRACELLULARLY CLEAVABLE MOIETIES BIOSPAN CORP (US) 1995-05-17 EP disclosed
EP-0587440-A2 Catalyst component for the polymerisation of olefins and process for preparing olefin polymers using same NIPPON OIL COMPANY, LIMITED (JP) 1994-03-16 EP disclosed
EP-0482185-A1 CELL INTERNALIZABLE CONJUGATES AND COMPLEXES INCLUDING INTRACELLULARLY CLEAVABLE MOIETIES ANERGEN, INC. (US) 1992-04-29 EP disclosed
WO-1991018012-A1 CELL INTERNALIZABLE CONJUGATES AND COMPLEXES INCLUDING INTRACELLULARLY CLEAVABLE MOIETIES BIOSPAN CORPORATION (US) 1991-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160645-A1 POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS GNE, EPRS1, ALG1 KIF11 2303/4885
US-20160354480-A1 ACTIVATED NEUROTENSIN MOLECULES AND THE USES THEREOF NTSR2, NTSR1, NTRK2 KIF11 1829/4885
US-20080207913-A1 Poly(ethylene glycol) containing chemically disparate endgroups GNE, EPRS1, ALG1 KIF11 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.